Mission Statement, Vision, & Core Values of SI-BONE, Inc. (SIBN)

A company's Mission, Vision, and Core Values are not just posters on a wall; they are the strategic bedrock that drives financial performance, especially for a medical device company like SI-BONE, Inc. (SIBN) which is on track for a 2025 worldwide revenue of between $198 million and $200 million, representing up to 20% growth. When you see Q3 2025 adjusted EBITDA turn positive at $2.3 million, you have to ask: is this operational efficiency or is it a direct result of their stated mission to help patients rise up and reach for the stars? We need to understand the principles guiding a company with an approximate $804 million market capitalization, so how do their core values-Purpose-Driven, Agile, Creative, and One Team-map to their market disruption and their 27% growth in active U.S. physicians?

SI-BONE, Inc. (SIBN) Overview

You need a clear picture of SI-BONE, Inc. (SIBN) to understand its market position, and the takeaway is simple: this company is the clear pioneer in a high-growth, underserved area of spine care, and their latest financials confirm they are defintely moving toward sustainable profitability.

SI-BONE, a medical device company founded in 2008, essentially created the market for minimally invasive sacroiliac (SI) joint fusion surgery. The SI joint is a common but often misdiagnosed source of chronic lower back pain, and SI-BONE's flagship product, the iFuse Implant System, was the first proprietary system to address this. They started pioneering this technology in 2009, and thousands of surgeons worldwide have since adopted the procedure.

The company's product portfolio has expanded beyond the original iFuse Implant System to include advanced, 3D-printed titanium implants like iFuse-3D, iFuse TORQ, and iFuse Bedrock Granite. These products treat a range of sacropelvic disorders, including SI joint dysfunction, adult spinal deformity, and pelvic trauma. For the trailing twelve months ending September 30, 2025, SI-BONE reported revenue of approximately $194 million, showing strong momentum. That's a solid run rate.

Breaking Down Q3 2025 Financial Performance

The third quarter of 2025 (Q3 2025) results, released in November 2025, showcase the company's operational strength and scalability. Worldwide revenue hit a record $48.7 million, marking a significant 20.6% increase compared to the same quarter last year. Honestly, that kind of consistent topline growth is exactly what you want to see in a med-tech company.

Here's the quick math on where that growth is coming from:

• U.S. Revenue: $46.4 million, a 21.2% year-over-year jump, driven by strong procedure demand.
• International Revenue: $2.3 million, up 10.2%, benefiting from the European launch of the iFuse TORQ system.
• Physician Adoption: Active U.S. physicians using their technology grew 27% to 1,530 in the quarter.

Plus, the company is getting closer to full profitability. Adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) turned positive, reaching $2.3 million in Q3 2025. The gross margin is also impressive, improving to 79.8%. What this estimate hides is the continued investment in R&D and commercial expansion, but the trajectory is clear: they are generating cash from operations and narrowing their net loss to just $4.6 million for the quarter.

A Clear Leader in Sacropelvic Solutions

SI-BONE is not just another player; it is a global leader in surgical technology for sacropelvic disorders. The company's success isn't just based on sales, but on clinical evidence-a crucial factor in the medical device space. They have over 100 peer-reviewed publications supporting their technology, including two randomized controlled trials, which is a rare and powerful differentiator.

Their full-year 2025 worldwide revenue guidance is now projected to be between $198 million and $200 million, which implies year-over-year growth in the range of 18% to 20%. This confidence comes from their differentiated platform, which includes the iFuse Bedrock Granite and iFuse TORQ TNT systems, the latter of which now qualifies for a New Technology Add-on Payment (NTAP) of over $4,100 per procedure, enhancing reimbursement. To understand the full financial picture behind this success, you should look at Breaking Down SI-BONE, Inc. (SIBN) Financial Health: Key Insights for Investors.

SI-BONE, Inc. (SIBN) Mission Statement

You're looking for the core driver behind SI-BONE, Inc.'s strong financial momentum-a company that just raised its full-year 2025 revenue guidance to a range of $198 million to $200 million. The direct takeaway is that their mission, Helping patients rise up and reach for the stars, is not just a feel-good phrase; it's a strategic compass that dictates capital allocation, product development, and commercial strategy, directly fueling an estimated 18% to 20% annual growth rate.

A mission statement is the anchor for any successful, publicly-traded medical device company, especially one focused on a niche like sacropelvic disorders. For SI-BONE, this statement is the foundation for their long-term vision: Ambitiously growing and disrupting the spinopelvic market with innovative solutions supported by world-class evidence, education, advocacy, and clinical support. This clarity helps investors and employees alike understand where the company is going and how they plan to get there. It's a defintely clear roadmap.

If you want a deeper dive into the company's origin and business model, you can check out SI-BONE, Inc. (SIBN): History, Ownership, Mission, How It Works & Makes Money.

Core Component 1: Patient-Centric Purpose (Helping Patients Rise Up)

The first and most human component of the mission is its focus on the patient: Helping patients rise up. This empathetic language translates directly into targeting an underserved and often misdiagnosed market-the sacroiliac (SI) joint. The company's core value, Purpose-Driven, underpins this by ensuring every product and decision is tied back to improving patient mobility and quality of life.

Here's the quick math on their impact: SI-BONE has supported over 4,900 physicians in performing a total of over 135,000 procedures since 2009. This massive procedure count shows the scale of their patient commitment. In the third quarter of 2025 alone, the number of active U.S. physicians using their technology-like the iFuse Implant System®-grew by 27% to 1,530, meaning more patients are accessing these transformative, minimally invasive treatments. That kind of physician adoption proves the patient outcome is real.

• Focus on underserved sacropelvic disorders.
• Translate patient need into commercial success.
• Drive physician adoption through clinical results.

Core Component 2: Market Disruption through Innovation (Ambitiously Growing and Disrupting)

The vision statement calls for Ambitiously growing and disrupting the spinopelvic market, which is where the financial results start to align with the mission. Disruption requires constant innovation, which is captured in their core value of Creative. SI-BONE is not content with its pioneering iFuse system; it's expanding its platform with products like iFuse TORQ and iFuse Bedrock Granite to address adjacent markets like adult deformity and pelvic trauma. This is where the growth comes from.

The company's financial performance in 2025 demonstrates this ambition. They delivered $48.7 million in worldwide revenue in Q3 2025, a jump of 20.6% year-over-year. This growth is scalable, too. The company achieved a positive adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of $2.3 million in Q3 2025, showing they are managing operating expenses effectively while still investing in new product rollouts, like the successful launch of iFuse TORQ in Europe. They are growing fast, but they are also getting smarter about it.

Core Component 3: World-Class Evidence and Support (Supported by World-Class Evidence)

In the medical device space, a great implant is useless without clinical proof and reimbursement. This component of the vision-supported by world-class evidence, education, advocacy, and clinical support-is the critical bridge between innovation and market acceptance. Their core values of Agile and One Team are vital here, as they must quickly respond to regulatory and clinical needs.

SI-BONE has built a formidable body of evidence, including over 180 peer-reviewed publications and four randomized controlled trials. This evidence is what drives major reimbursement wins, which directly impacts the bottom line. For example, the iFuse TORQ TNT system procedures now qualify for a New Technology Add-on Payment (NTAP) of over $4,100 effective October 1, 2025, a clear signal that the Centers for Medicare & Medicaid Services (CMS) recognizes the clinical benefit of the technology. Furthermore, the company's full-year 2025 gross margin is estimated to be around 79.5%, a figure that reflects the premium pricing and strong operational efficiency that this evidence-based market leadership commands.

SI-BONE, Inc. (SIBN) Vision Statement

You're looking for the anchor points of SI-BONE, Inc.'s strategy-the mission, vision, and values that drive their financial performance. The direct takeaway is that SI-BONE is successfully executing a high-growth, innovation-led vision, translating clinical leadership into tangible financial gains like positive adjusted EBITDA in 2025.

The company's focus isn't just on selling devices; it's on a market disruption strategy for the entire spinopelvic space. This commitment is what underpins their expected full-year 2025 worldwide revenue guidance of $198 million to $200 million, a strong signal of commercial momentum.

Mission Statement: Helping Patients Rise Up

The mission is simple and empathetic: Helping patients rise up and reach for the stars. This is the emotional core that justifies the significant investment in clinical evidence and physician training. SI-BONE is focused on the sacroiliac (SI) joint, an area of orthopedics that has historically been underserved, under-diagnosed, and under-treated.

To be fair, a mission statement isn't a financial metric, but it drives the economics. Since pioneering minimally invasive SI joint surgery in 2009 with the iFuse Implant System, the company has supported over 4,600 physicians in performing nearly 130,000 procedures. That's a massive patient base that validates the mission's impact. The procedure volume is defintely the most important operational indicator of this mission's success.

Vision Component: Ambitiously Growing and Disrupting the Spinopelvic Market

SI-BONE's vision is about market expansion and disruption: Ambitiously growing and disrupting the spinopelvic market with innovative solutions. This isn't just about the SI joint anymore; it's about leveraging their core technology, the iFuse Technology platform, into adjacent high-value markets like adult deformity and pelvic trauma.

Here's the quick math on that growth: The company reported Q3 2025 worldwide revenue of $48.7 million, representing a 20.6% year-over-year increase. More importantly, the active U.S. physician base grew by 27% to 1,530 in Q3 2025, which shows the market is buying into the disruption vision. That's a strong leading indicator for future revenue growth, and it's why they've been able to raise their 2025 revenue guidance. For a deeper dive on who is investing in this growth story, you should check out Exploring SI-BONE, Inc. (SIBN) Investor Profile: Who's Buying and Why?

Vision Component: Innovative Solutions and World-Class Evidence

The second half of the vision focuses on the execution mechanism: supported by world-class evidence, education, advocacy, and clinical support. This is where the company differentiates itself from smaller players-it's the classic med-tech playbook of using data to drive adoption and reimbursement.

The clinical evidence is substantial, with over 175 peer-reviewed publications, including four randomized controlled trials. This evidence directly translates to financial opportunity, especially with reimbursement. For example, the New Technology Add-on Payment (NTAP) for procedures involving iFuse TORQ TNT became effective on October 1, 2025, providing an additional payment of over $4,100 per procedure. This is a huge tailwind for their latest innovation, iFuse TORQ TNT, and a clear sign that the evidence-based strategy is paying off.

The operational efficiency of this model is clear in the gross margin. The full-year 2025 gross margin is estimated to be around 79.5%, which is a high-quality number for a medical device company.

Core Values in Action: The Path to Profitable Growth

SI-BONE's core values-Purpose-Driven, Agile, Creative, and One Team-are the internal compass for achieving their ambitious vision. These values are what allow them to operate with an asset-light business model and still achieve profitability milestones.

• Purpose-Driven: Focuses the team on the mission, which helps keep operating expenses in check.
• Agile: Allows for quick commercialization of new products like iFuse TORQ in Europe.
• Creative: Drives the development of the deep pipeline of novel technologies, as CEO Laura Francis has noted.
• One Team: Essential for coordinating the salesforce of approximately 160 field representatives with the nearly 200 support employees.

The result of this disciplined approach is the shift toward profitability. The company delivered positive adjusted EBITDA of $2.3 million in Q3 2025, a significant improvement from the prior year. They also ended Q3 2025 with $145.7 million in cash and equivalents, providing a solid foundation to self-fund innovation and drive that industry-leading profitable growth. Finance: Monitor the adjusted EBITDA trend to confirm full-year positive guidance is met.

SI-BONE, Inc. (SIBN) Core Values

You're looking for the bedrock principles that drive a medical device company's financial performance, and for SI-BONE, Inc., it all starts with the patient. The company's mission-Helping patients rise up and reach for the stars-is more than a slogan; it's the lens through which we should view their 2025 operational success.

Their vision is to be a disruptive leader in the spinopelvic market, backed by world-class evidence. That focus translates directly into the four core values that underpin their strong fiscal year 2025 results, including a worldwide revenue guidance of $198 million to $200 million. That's an impressive 18% to 20% year-over-year growth, showing their values aren't just words on a wall; they're an operating manual.

Purpose-Driven

Being Purpose-Driven means every decision ties back to the patient, and for SI-BONE, Inc., this commitment is most visible in their clinical evidence and physician network expansion. They are focused on treating the sacroiliac (SI) joint, an area often under-diagnosed, and their mission dictates a tireless pursuit of patient outcomes.

Here's the quick math on their impact: the company has supported over 4,900 physicians in performing more than 135,000 procedures with their technology, like the iFuse Implant System. In the third quarter of 2025 alone, the number of active U.S. physicians grew by 27% to 1,530. You simply don't see that kind of adoption unless the product, and the evidence behind it, is defintely working for the patient.

• Maintain over 180 peer-reviewed publications on their technology.
• Focus on sacropelvic disorders, an underserved area of orthopedics.
• Drive procedure volume growth over 22% in the U.S. in Q3 2025.

Creative

The Creative value is all about embracing new solutions and challenging the status quo, which in the medical device world means aggressive, smart innovation. This value is the engine behind their expanding iFuse Technology platform, moving beyond the initial SI joint fusion to adjacent markets like adult deformity and pelvic trauma.

The launch of new products like iFuse TORQ TNT and iFuse Bedrock Granite is a direct result of this creative drive. Crucially, the Centers for Medicare & Medicaid Services (CMS) confirmed the New Technology Add-On Payment (NTAP) for procedures involving iFuse TORQ TNT, effective October 1, 2025, which pays an additional amount up to $4,136. That's a clear financial validation of their innovative technology's clinical benefit and market disruption.

Agile

Agility is the ability to learn and respond quickly to stakeholder needs-physicians, regulators, and the market. For SI-BONE, Inc., this means rapidly commercializing new products and adapting their sales strategy to maximize reach. You can see this agility in their international expansion and commercial execution.

The international rollout of iFuse TORQ, for example, began in Europe in July 2025. This quick move to new markets helped international revenue climb by 10.2% in Q3 2025. Also, the trailing 12-month average revenue per territory increased by 16% in Q3 2025, a sign that their sales force is adapting quickly and effectively to new product launches and market demand.

One Team

The One Team value is the internal commitment to collaboration and making things happen, which is critical for turning high growth into profitability. It's the operational excellence that makes the whole machine run efficiently. This is where the financial discipline comes into play.

In the third quarter of 2025, the company reported a positive adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of $2.3 million, a significant swing from a loss in the prior year. Total operating expenses grew by 11.9% year-over-year, which is substantially lower than the 20.6% worldwide revenue growth. This operating leverage-growing sales faster than costs-is the clearest indicator that the entire organization is working as one disciplined, efficient team to achieve profitability and scale.